Want to see AU:SNT full AI Analyst Report?
Top Page
Syntara Limited
(Sydney:SNT)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.02
▼(-40.00% Downside)
Action:Reiterated
Date:10/17/26
The score is driven primarily by weak financial performance (no recent revenue, ongoing losses, and sustained negative operating/free cash flow). Technicals add downside pressure with the price below key moving averages and negative momentum indicators. A low-debt balance sheet provides some stability, but it is not enough to offset the current lack of profitability and cash generation.
Positive Factors
Low Leverage
The absence of debt and sizeable equity base reduce solvency and refinancing pressure compared with earlier periods of higher leverage. This gives Syntara greater balance-sheet flexibility to support clinical development and absorb operating volatility over the next several quarters.
Negative Factors
No Recent Revenue
The absence of reported revenue means Syntara currently lacks an established commercial earnings stream to fund operations or validate market adoption. This leaves future financial performance dependent on successful development and eventual commercialisation rather than recurring business activity.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
The absence of debt and sizeable equity base reduce solvency and refinancing pressure compared with earlier periods of higher leverage. This gives Syntara greater balance-sheet flexibility to support clinical development and absorb operating volatility over the next several quarters.
Read all positive factors
Syntara Limited (SNT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$36.34M
Dividend YieldN/A
Average Volume (3M)1.93M
Price to Earnings (P/E)―
Beta (1Y)2.70
Revenue GrowthN/A
EPS Growth-8.00%
CountryAU
Employees85
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,964,519,300
10 Day Avg. Volume1,310,725
30 Day Avg. Volume1,932,490
Financial Highlights & Ratios
PEG Ratio-0.47
Price to Book (P/B)1.91
Price to Sales (P/S)4.48
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Syntara Limited Business Overview & Revenue Model
Company Description
Syntara Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies by targeting extracellular matrix dysfunction, primarily through amine oxidase chemistry. Headquartered in Frenchs Forest, Australia, the co...
Syntara Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Jun 2026 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.93M | 7.30M | 5.76M | 5.76M | 7.43M |
| Gross Profit | -450.00K | -223.00K | 3.06M | 3.06M | 7.43M |
| EBITDA | -16.21M | -12.00M | -10.90M | -17.99M | 637.00K |
| Net Income | -8.99M | -7.92M | -11.36M | -1.94M | -2.97M |
Balance Sheet | |||||
| Total Assets | 19.14M | 21.44M | 24.03M | 25.19M | 33.59M |
| Cash, Cash Equivalents and Short-Term Investments | 13.56M | 15.08M | 9.23M | 8.94M | 18.71M |
| Total Debt | 0.00 | 84.00K | 2.04M | 4.29M | 6.32M |
| Total Liabilities | 2.92M | 5.42M | 14.47M | 14.38M | 30.75M |
| Stockholders Equity | 16.21M | 16.02M | 9.56M | 10.80M | 2.85M |
Cash Flow | |||||
| Free Cash Flow | -9.78M | -11.12M | -7.42M | -16.61M | 2.42M |
| Operating Cash Flow | -9.78M | -11.12M | -7.28M | -16.30M | 3.07M |
| Investing Cash Flow | -2.00K | 4.18M | -131.00K | -306.00K | -644.00K |
| Financing Cash Flow | 8.26M | 18.46M | 6.98M | 6.63M | 1.52M |
Syntara Limited Technical Analysis
Negative
0.03
Price Trends
0.02
Negative
0.02
Negative
0.03
Negative
Market Momentum
>-0.01
Negative
38.18
Neutral
88.89
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:SNT, the sentiment is Negative. The current price of 0.03 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and above the 200-day MA of 0.03, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 38.18 is Neutral, neither overbought nor oversold. The STOCH value of 88.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:SNT.
Syntara Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | AU$8.30M | 0.30 | 64.70% | ― | -24.22% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$49.68M | -13.04 | -1.67% | ― | 15.21% | -141.82% | |
44 Neutral | AU$13.25M | -2.99 | -9.80% | 10.53% | 5.74% | -222.22% | |
43 Neutral | AU$2.72M | -0.59 | -50.35% | ― | -4.87% | -9.78% | |
41 Neutral | AU$36.34M | -3.43 | -67.08% | ― | ― | -8.00% | |
39 Underperform | AU$21.43M | -5.07 | 4388.00% | ― | -19.73% | 50.34% |
* Healthcare Sector Average
AU:SNT
Syntara Limited
0.02
-0.01
-41.94%
AU:EXL
Elixinol Wellness
0.02
<0.01
25.00%
AU:CAN
Cann Group
0.01
>-0.01
-9.09%
AU:LGP
Little Green Pharma Ltd.
0.06
-0.07
-53.85%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-23.81%
AU:VIT
Cronos Australia Ltd.
0.02
-0.04
-67.74%
Syntara Limited Corporate Events
Syntara Flags Risks Around Drug and Device Pipeline
Oct 12, 2026
Syntara Limited operates in the pharmaceutical and medical device sector, focusing on the development of drug and device products and product candidates. The company’s activities center on advancing its pipeline and seeking commercial partne...
Syntara Issues New Unquoted Performance Rights Under Employee Incentive Plan
Oct 5, 2026
Syntara Limited has notified the market of the issue of 1,581,746 unquoted performance rights under its employee incentive scheme. These SNTAAS securities are subject to transfer restrictions and will not be quoted on the ASX until those restricti...
Syntara Issues 34.9 Million Unquoted Performance Rights Under Incentive Scheme
Oct 5, 2026
Syntara Limited, traded on the ASX under ticker SNT, is an Australian public company that employs equity-based remuneration, including unquoted performance rights, to reward staff and support long-term alignment between management, employees and s...
Syntara Expands SNT-9465 Scar Trial as Early SNT-6302 Data Shape Strategy
Oct 1, 2026
Syntara Limited is a clinical-stage biopharmaceutical company developing topical pan-lysyl oxidase inhibitors to address hypertrophic and keloid skin scarring, areas with limited effective treatment options. Its lead programs, SNT-9465 and SNT-630...
Syntara boosts R&D funding with A$4.7m tax incentive
Sep 20, 2026
Syntara Limited has secured an A$4.7 million Research and Development Tax Incentive refund from the Australian Government for eligible activities undertaken in the 2026 financial year. The incentive, which returns a significant proportion of quali...
Syntara Seeks ASX Quotation for 1.5 Million New Shares
Sep 15, 2026
Syntara Limited has lodged an application with the ASX for quotation of 1,500,000 new ordinary fully paid shares under its existing issuer code SNT. The securities, issued on 15 September 2026, will expand the company’s quoted share capital ...
Syntara Sets 2026 AGM Date as It Refocuses on Fibrosis and Cancer Pipeline
Sep 15, 2026
Syntara Limited, an ASX-listed clinical-stage biotechnology company based in Sydney, develops drugs targeting extracellular matrix dysfunction for blood cancers and fibrotic and inflammatory diseases, led by its amsulostat program in myelofibrosis...
Syntara Loss Widens as Revenue Falls and Asset Base Shrinks
Aug 27, 2026
For the 2026 financial year, Syntara reported a 7.9% decline in revenues and other income to $7.0 million and a 13.6% increase in net loss to $9.0 million, with no dividends paid or declared for either the current or prior year. Net tangible asset...
Syntara to Brief Investors on Expanding Clinical Pipeline in Quarterly Webinar
Jul 27, 2026
Syntara Limited will host an investor webinar on 28 July 2026 to provide an update on recent announcements and its latest quarterly cash flow report, with CEO Gary Phillips presenting the company’s progress and outlook. The session, which of...
Syntara secures FDA backing and funding as key clinical programs advance
Jul 26, 2026
Syntara Limited reported a pivotal June quarter, marked by positive U.S. FDA feedback endorsing the design of a ~100-patient Phase 2b trial of lead candidate amsulostat in myelofibrosis, reinforcing its path toward late-stage development and bolst...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.